EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives

Yongshun Liu, Kexin Lan, Zhaonan Sun, Wenpeng Huang

Pharmaceuticals · 13.07.2026 · 19 (7) · 1078

DOI: 10.3390/ph19071078 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.07.2026. Verfasst von Yongshun Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, Peking University First Hospital, Beijing 100034, China. Die Arbeit nennt 229 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University First Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer ranks among the most lethal malignancies, characterized by a five-year survival rate of approximately 10%. This dismal prognosis is largely attributable to diagnoses occurring at advanced stages and the inherent limitations of conventional imaging modalities in detecting early lesions, identifying metastases, and assessing tumor heterogeneity. Consequently, there is a critical need for non-invasive imaging techniques capable of visualizing pancreatic cancer lesions to enable accurate diagnosis, risk assessment, and the development of personalized treatment strategies. Molecular imaging, which combines highly specific targeted probes with advanced imaging technologies, offers the potential to elucidate disease-associated pathways. This review provides a comprehensive overview of recent advancements in molecular imaging platforms for pancreatic cancer, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), optical molecular imaging, photoacoustic imaging, and molecular MRI. We begin by elucidating the biological rationale for targeting key molecules, including fibroblast activation protein (FAP), integrins, and programmed death ligand 1 (PD-L1). Moreover, we critically evaluate the development and clinical translation of these probes, highlighting their ability to enhance lesion detectability, characterize intratumoral heterogeneity, and guide both targeted therapy and surgical resection. Compared with existing reviews, this work uniquely integrates a comprehensive cross-modality analysis of the latest molecular imaging strategies for pancreatic cancer. Furthermore, we examine prevailing challenges and emerging frontiers in this domain, specifically focusing on multimodal hybrid imaging, artificial intelligence-driven analytics, and integrated theranostic platforms as pivotal strategies to advance precision oncology.

Schlagwörter

Stichwörter der Autor:innen

fibroblast activation proteinintegrinmolecular imagingpancreatic cancerpositron-emission tomography

Autor:innen und Institutionen

  • Department of Medical Imaging, Peking University First Hospital, Beijing 100034, China.
  • Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
  • Department of Radiology, Geriatric Hospital of Nanjing Medical University (Jiangsu Province Official Hospital), Nanjing 210024, China.

Förderung

  • Peking University First Hospital

Zitieren

APA

Liu, Y., Lan, K., Sun, Z., & Huang, W. (2026). Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives. Pharmaceuticals, 19(7), 1078. https://doi.org/10.3390/ph19071078

Vancouver

Liu Y, Lan K, Sun Z, Huang W. Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives. Pharmaceuticals. 2026;19(7):1078. doi:10.3390/ph19071078

BibTeX
@article{Liu2026,
  author = {Liu, Yongshun and Lan, Kexin and Sun, Zhaonan and Huang, Wenpeng},
  title = {Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1078},
  doi = {10.3390/ph19071078}
}
Kostenlos starten →